News and Events
SNX-5422 clinical profile supports development in multiple indications in both solid and hematologic tumors and advancement toward pivotal trials
Interested in a potential clinical study of rational drug combinations with SNX-5422?
Through it’s work to define the details of SNX-5422’s mode of action, Esanex has identified target mechanisms where efficacy is predicated to be driven by complementary rather than redundant mechanisms. Please contact us at firstname.lastname@example.org with your specific interest.